CXCR4 and B-cell chronic lymphocytic leukemia: These findings underscore the potential of clinically approved inhibitors, along with IL‐10 and CXCR4 blockade, to support CAR T‐cell‐mediated cytotoxicity, alleviate CAR T‐cell exhaustion, and counteract the immunosuppressive and protective characteristics of the CLL microenvironment.